Ocular vascular thrombotic events: Central retinal vein and central retinal artery occlusions

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 3, 2008, Pages 286-294

  Glueck, Charles J ^a   Wang, Ping ^a   Hutchins, Robert ^b   Petersen, Michael R ^c   Golnik, Karl ^b  

^a JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c CINCINNATI EYE INSTITUTE   (United States)

Author keywords

Central retinal artery thrombosis; Central retinal vein thrombosis; Hypofibrinolysis; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; VERY LATE ACTIVATION ANTIGEN 2;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; GENE MUTATION; HUMAN; LABORATORY DIAGNOSIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; THROMBOPHILIA;

ADULT; AGED; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RETINAL ARTERY; RETINAL ARTERY OCCLUSION; RETINAL VEIN OCCLUSION; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 45749131016     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607304726     Document Type: Article

References (83)

1. Glueck CJ, Bell H., Vadlamani L., et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol. 1999 ; 117: 43-49.
2. Greiner K., Hafner G., Dick B., Peetz D., Prellwitz W., Pfeiffer N. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol. 1999 ; 128: 69-74.
3. Hansen L., Kristensen HL, Bek T., Ingerslev J. Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand. 2000 ; 78: 523-526.
4. Larsson J., Hillarp A., Olafsdottir E., Bauer B. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand. 1999 ; 77: 634-637.
5. Pianka P., Almog Y., Man O., Goldstein M., Sela BA, Loewenstein A. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology. 2000 ; 107: 1588-1592.
6. Klein R., Klein BE, Moss SE, Meuer SM The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000 ; 98: 133-141 ; discussion 141-143.
7. Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol. 1993 ; 115: 162-167.
8. von Mach MA, Güz A., Wiechelt J., Pfeiffer N., Weilemann LS Systemic fibrinolytic therapy using urokinase in central retinal artery occlusion. A case study [in German]. Dtsch Med Wochenschr. 2005 ; 130: 1002-1006.
9. Ozdek S., Yülek F., Gürelik G., Avdin B., Hasanreiso?lu B. Simultaneous central retinal vein and retinal artery branch occlusions in two patients with homocystinaemia. Eye. 2004 ; 18: 942-945.
10. Ben-Ami R., Zeltser D., Leibowitz I., Berliner SA Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations. Blood Coagul Fibrinolysis. 2002 ; 13: 57-59.
11. Vielpeau I., Le Hello C., Legris A., Salsou E., Lecog PJ Retinal vascular occlusion and primary antiphospholipid syndrome. Report of 2 cases [in French]. J Fr Ophtalmol. 2001 ; 24: 955-960.
12. Salomon O., Huna-Baron R., Moisseiev J., et al. Thrombophilia as a cause for central and branch retinal artery occlusion in patients without an apparent embolic source. Eye. 2001 ; 15: 511-514.
13. Greiner K., Peetz D., Winkgen A., Prellwitz W., Pfeiffeer N., Hafner G. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol. 1999 ; 23: 155-160.
14. Bertram B., Remky A., Arend O., Wolf S., Reim M. Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol. 1995 ; 4: 332-335.
15. Akar N., Gokce H. High levels of FVIII and FIX in a pediatric patient with retinal artery occlusion. Pediatr Hematol Oncol. 2002 ; 19: 593-595.
16. Glueck CJ, Fontaine RN, Wang P. Interaction of heritable and estrogen-induced thrombophilia: possible etiologies for ischemic optic neuropathy and ischemic stroke. Thromb Haemost. 2001 ; 85: 256-259.
17. Glueck CJ, Wang P., Bell H., Rangaraj V., Goldenberg N. Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation. J Lab Clin Med. 2004 ; 143: 184-192.
18. Larsson J. Central retinal artery occlusion in a patient homozygous for factor V Leiden. Am J Ophthalmol. 2000 ; 129: 816-817.
19. Leifert D., Auw-Hädrich C., Leifert JA Arterial ocular occlusion associated with systemic venous thrombophilia-2 case reports [in German]. Klin Monatsbl Augenheilkd. 2006 ; 223: 908-913.
20. Srinivasan S., Fern A., Watson WH, McColl MD Reversal of nonarteritic anterior ischemic optic neuropathy associated with coexisting primary antiphospholipid syndrome and Factor V Leiden mutation. Am J Ophthalmol. 2001 ; 131: 671-673.
21. Glueck CJ, Goldenberg N., Bell H., Golnik K., Wang P. Amaurosis fugax: associations with heritable thrombophilia. Clin Appl Thromb Hemost. 2005 ; 11: 235-241.
22. Bick RL, Alfar H., Goedecke. C Thrombophilic causes of retinal vascular thrombosis: etiology and treatment outcomes. Clin Appl Thromb Hemost. 2002 ; 8: 315-318.
23. Glueck CJ, Wang P., Bell H., Rangaraj V., Goldenberg N. Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion. Clin Appl Thromb Hemost. 2005 ; 11: 375-389.
24. Scott JA, Arnold JJ, Currie JM, et al. No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. Ophthalmologica. 2001 ; 215: 217-221.
25. Kadayifcilar S., Ozatli D., Ozcebe O., Sener EC Is activated factor VII associated with retinal vein occlusion ? Br J Ophthalmol. 2001 ; 85: 1174-1178.
26. Incorvaia C., Bandello F., Parmeggiani F., D'Angelo S., Costagliola C., Sebastiani A. Recurrent central retinal vein occlusion in a young thrombophilic patient with factor V Leiden mutation. Eur J Ophthalmol. 2002 ; 12: 131-134.
27. Arsene S., Delahousse B., Regina S., Le Lez ML, Pisella PJ, Gruel V. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost. 2005 ; 94: 101-106.
28. Duic J., Gveri-Krecak V. Recurrent incomplete central retinal vein occlusion in a patient with hereditary thrombophilia [in Croatian]. Acta Med Croatica. 2006 ; 60: 171-174.
29. Gao W., Wang YS, Zhang P., Wang HY Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol. 2006 ; 244: 1246-1249.
30. Lattanzio R., Sampietro F., Ramoni A., Fattorini A., Brancato R., D'Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina. 2006 ; 26: 65-70.
31. Janssen MC, den Heijer M., Cruysberg JR, Wollersheim H., Bredie SJ Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost. 2005 ; 93: 1021-1026.
32. Cahill M., O'Toole L., Acheson RW Hormone replacement therapy and retinal vein occlusion. Eye. 1999 ; 13 (Pt 6). 798-800.
33. Edwards M., Longstaff S., Makris M. Retinal vein occlusion, the contraceptive pill and the prothrombin 20210A allele. Eye. 1999 ; 13 (Pt 2). 269.
34. Kirwan JF, Tsaloumas MD, Vinall H., Prior P., Kritzinger EE, Dodson PM Sex hormone preparations and retinal vein occlusion. Eye. 1997 ; 11 (Pt 1). 53-56.
35. Vessey MP, Hannaford P., Mant J., Painter R., Frith P., Chappel D. Oral contraception and eye disease: findings in two large cohort studies. Br J Ophthalmol. 1998 ; 82: 538-542.
36. Martinelli I. Unusual forms of venous thrombosis and thrombophilia. Pathophysiol Haemost Thromb. 2002 ; 32: 343-345.
37. Bombeli T., Basic A., Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002 ; 70: 126-132.
38. Rodeghiero F., Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999 ; 130: 643-650.
39. Glueck CJ, Freiberg RA, Fontaine RN, Sieve-Smith L., Wang P. Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia. Expert Opin Investig Drugs. 200110: 1309-1316.
40. Glueck CJ, Pranikoff J., Aregawi D., et al. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. Metabolism. 200554: 1345-1349.
41. Glueck CJ, Wang P., Bornovali S., Goldenberg N., Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003 ; 52: 1627-1632.
42. Balasa VV, Gruppo RA, Glueck CJ, et al. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004 ; 86-A: 2642-2647.
43. Balasa VV, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost. 1999 ; 81: 739-744.
44. Glueck CJ, Iyengar S., Goldenberg N., et al. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med. 2003 ; 142: 35-45.
45. Glueck CJ, Aregawi D., Goldenberg N., Smith LS, Wang P. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. J Lab Clin Med. 2005: 145: 72-82.
46. Glueck CJ, Glueck HI, Tracy T., Speirs J., McCray C., Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism. 1993 ; 42: 236-246.
47. Glueck CJ, Freiberg RA, Fontaine RN, Tracy T., Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res 2001 ;(386) 19-33.
48. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 ; 287: 356-359.
49. Flegal KM, Carroll MD, Ogden CL, Johnson CL Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002 ; 288: 1723-1727.
50. Health NIo. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). 2001.
51. Colucciello M. Retinal vascular disease in hypertension. Risk factor modification optimizes vision outcomes. Postgrad Med. 2005 ; 117: 33-38, 41-42.
52. Mitchell P., Smith W., Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996 ; 114: 1243-1247.
53. Guven D., Sayinalp N., Kalayci D., Dündar S., Hasiripi H. Risk factors in central retinal vein occlusion and activated protein C resistance. Eur J Ophthalmol. 1999 ; 9: 43-48.
54. Grundy SM Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007 ; 92: 399-404.
55. Undas A., Kubicka-Trzaska A. Thrombophilia as a risk factor for central retinal vein occlusion [in Polish]. Klin Oczna. 2003 ; 105: 221-224.
56. Lahey JM, Tunc M., Kearney J., et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology. 2002 ; 109: 126-131.
57. Traipe L., Conte G., Conte FJ, et al. Markers of thrombophilia in patients with retinal vein thrombosis [in Spanish]. Rev Med Chil. 2005 ; 133: 167-174.
58. Faude F., Faude S., Siegemund A., Wiedemann P. Factor VIII activity in patients with central retinal vein occlusion in comparison to patients with a history of pelvic and lower limb venous thrombosis and a healthy control group [in German]. Klin Monatsbl Augenheilkd. 2004 ; 221: 862-866.
59. Gumus K., Kadayifcilar S., Eldem B., et al. Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion ? Clin Experiment Ophthalmol. 2006 ; 34: 305-311.
60. Boyd S., Owens D., Gin T., et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001 ; 85: 1313-1315.
61. Glueck CJ, Shaw P., Lang JE, Tracy T., Sieve-Smith L., Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995 ; 75: 132-136.
62. Tekeli O., Gursel E., Buyurgan H. Protein C, protein S and antithrombin III deficiencies in retinal vein occlusion. Acta Ophthalmol Scand. 1999 ; 77: 628-630.
63. Hoibraaten E., Qvigstad E., Andersen TO, Mowinckel MC, Sandset PM The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial. Thromb Haemost. 2001 ; 85: 775-781.
64. Post MS, Rosing J., Van Der Mooren MJ, et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol. 2002 ; 119: 1017-1023.
65. Post MS, Christella M., Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in post-menopausal women. Arterioscler Thromb Vasc Biol. 2003 ; 23: 1116-1121.
66. Chua B., Kifley A., Wong TY, Mitchell P. Homocysteine and retinal emboli: the Blue Mountains Eye Study. Am J Ophthalmol. 2006 ; 142: 322-324.
67. Cahill M., Karabatzaki M., Meleady R., et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000 ; 84: 154-157.
68. Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, Al-Attas OS Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol. 2002 ; 12: 495-500.
69. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003 ; 136: 1136-1150.
70. Koren-Michowitz M., Eting E., Rahimi-Levene N., Garach-Jehoshua O., Volcheck Y., Kornberg A. Protein Z levels and central retinal vein or artery occlusion. Eur J Haematol. 2005 ; 75: 401-405.
71. Bick RL, Ancypa D. The antiphospholipid and thrombosis (APL-T) syndromes. Clinical and laboratory correlates. Clin Lab Med. 1995 ; 15: 63-84.
72. Bick RL Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost. 2001 ; 7: 241-258.
73. Incorvaia C., Parmeggiani F., Costagliola C., et al. The heterozygous 20210 G/A genotype prevalence in patients affected by central and branch retinal vein occlusion: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2001 ; 239: 251-256.
74. Cheong JL, Bucknall R. Retinal vein thrombosis associated with a herbal phytoestrogen preparation in a susceptible patient. Postgrad Med J. 2005 ; 81: 266-267.
75. Holak HM, Holak NH, Holak S., Holak SA, Szymaniec S. Retinal vein branch occlusion and palsy of the N. abducens in protein S deficiency [in German]. Ophthalmologe. 2005 ; 102: 279-285.
76. Incorvaia C., Lamberti G., Parmeggiani F., et al. Idiopathic central retinal vein occlusion in a thrombophilic patient with the heterozygous 20210 G/A prothrombin genotype. Am J Ophthalmol. 1999 ; 128: 247-248.
77. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994 ; 117: 429-441.
78. Backhouse O., Parapia L., Mahomed I., Lee D. Familial thrombophilia and retinal vein occlusion. Eye. 2000 ; 14 (Pt 1). 13-17.
79. Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-1996. Vital Health Stat. 2000 ; 21: 1-47.
80. Parodi MB Medical treatment of retinal vein occlusions. Semin Ophthalmol. 2004 ; 19: 43-48.
81. Suarez Baraza J., Calzado Hinojosa J., Caracena Ordóñez JM, Miralles de Imperial J. Central retinal vein occlusion in a factor V Leiden and G21210A prothrombin variant carrier [in Spanish]. Arch Soc Esp Oftalmol. 2004 ; 79: 457-460.
82. Bick RL Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am. 2003 ; 17: 115-147.
83. Ota R., Okisaka S. Effects of anticoagulant therapy on retinal vein occlusion [in Japanese]. Nippon Ganka Gakkai Zasshi. 1995 ; 99: 955-958.